Michal Silverberg

Produces and markets fertilizers and chemical products

Discovers and develops inhibitors of validated metalloenzymes

Operates as a clinical-stage biopharmaceutical company which develops and commercializes novel therapeutics to transform the patient living

Functions as a College/University

Functions as a College/University

Takeda Ventures invests in companies located across the globe. The firm focuses on high-caliber, therapeutic, platform-based companies. It provides financing for early stage capital requirements.

Develops biological medicines

Develops, manufactures and markets lipid-based bioactive ingredients

Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors